urologic neoplasms

Summary

Summary: Tumors or cancer of the URINARY TRACT in either the male or the female.

Top Publications

  1. Gondo T, Ohori M, Hamada R, Tanaka A, Satake N, Takeuchi H, et al. The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen. Int J Clin Oncol. 2011;16:345-51 pubmed publisher
  2. Lughezzani G, Burger M, Margulis V, Matin S, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62:100-14 pubmed publisher
    ..The heterogeneity of upper tract urothelial carcinoma (UTUC) biology and prognosis, as well as the presence of different treatment options, makes the clinical decision-making process extremely challenging...
  3. Ling S, Chang X, Schultz L, Lee T, Chaux A, Marchionni L, et al. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res. 2011;71:3812-21 pubmed publisher
    ..These results identify a novel, potentially oncogenic signaling axis linking urothelial injury to UroCa. Inhibiting this axis is feasible through a variety of pharmacologic approaches and may have clinical utility...
  4. Favaretto R, Shariat S, Savage C, Godoy G, Chade D, Kaag M, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int. 2012;109:77-82 pubmed publisher
  5. Verhoest G, Shariat S, Chromecki T, Raman J, Margulis V, Novara G, et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol. 2011;29:495-501 pubmed publisher
    ..The objective of this article was to provide an updated overview of current clinical, pathological and biological prognostic factors of UTUC...
  6. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol. 2011;59:584-94 pubmed publisher
  7. Balar A, Apolo A, Ostrovnaya I, Mironov S, Iasonos A, Trout A, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013;31:724-30 pubmed publisher
    ..This trial evaluated the efficacy and safety of bevacizumab with GCa in advanced UC...
  8. Vassilakopoulou M, de La Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos M, et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer. 2011;117:5500-8 pubmed publisher
    ..Our objective was to assess the effect of adjuvant chemotherapy and the impact of potential prognostic factors on survival in high-risk, postsurgical UUT-UC patients...
  9. Pili R, Qin R, Flynn P, Picus J, Millward M, Ho W, et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013;11:477-83 pubmed publisher
    ..Pazopanib did not show significant activity in patients with urothelial carcinoma. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies. ..

More Information

Publications77

  1. Necchi A, Mariani L, Zaffaroni N, Schwartz L, Giannatempo P, Crippa F, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13:810-6 pubmed publisher
    ..We therefore investigated the activity and safety of pazopanib, a multitarget drug with antiangiogenic activity, in patients with urothelial cancer...
  2. Bellmunt J, Gonzalez Larriba J, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22:2646-53 pubmed publisher
    ..This trial was designed to assess the activity of sunitinib as first-line treatment in patients with metastatic urothelial cancer ineligible for cisplatin and to explore molecular and imaging variables predictive of clinical benefit...
  3. Yates D, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long J, et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer. 2012;106:1083-8 pubmed publisher
    ..A patient-specific survival nomogram based on such data is needed to predict cancer-specific survival (CSS) post nephroureterectomy (NU). Herein, we propose and validate a nomogram to predict CSS post NU...
  4. Choueiri T, Ross R, Jacobus S, Vaishampayan U, Yu E, Quinn D, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30:507-12 pubmed publisher
    ..Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy...
  5. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol. 2011;8:659-66 pubmed publisher
    ..CRP could, therefore, be an important biomarker for urological cancers...
  6. Ikeda M, Matsumoto K, Tabata K, Minamida S, Fujita T, Satoh T, et al. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J Clin Oncol. 2011;41:1214-20 pubmed publisher
  7. Cha E, Shariat S, Kormaksson M, Novara G, Chromecki T, Scherr D, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61:818-25 pubmed publisher
    ..Novel prognostic factors for patients after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) have recently been described...
  8. Majid S, Saini S, Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer. 2012;11:7 pubmed publisher
    ..An improved understanding of the basic genetics and biology of Wnt signaling pathway will provide insights into the development of novel chemopreventive and therapeutic strategies for urological cancers...
  9. Hsu L, Chiu A, Huan S, Chen C, Wang Y, Hsieh F, et al. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol. 2008;228:144-55 pubmed publisher
    ..These observations implied that impaired metabolism of carcinogenic exposure as well as impaired DNA repair function play an important role in arsenic-related urinary transitional cell carcinogenesis...
  10. Tai H, Lai M, Wang S, Chueh S, Yu H. High incidence of urinary tract malignancy among patients with haematuria following kidney transplantation in Taiwan. Transpl Int. 2009;22:403-7 pubmed publisher
    ..Those patients were also associated with significantly poorer graft function; however, the mechanism is still unclear...
  11. Twardowski P, Stadler W, Frankel P, Lara P, Ruel C, Chatta G, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76:923-6 pubmed publisher
    ..Evidence has shown that vascular endothelial growth factor is important in the pathophysiology of urothelial cancer...
  12. Kawakami K, Enokida H, Tachiwada T, Nishiyama K, Seki N, Nakagawa M. Increased SKP2 and CKS1 gene expression contributes to the progression of human urothelial carcinoma. J Urol. 2007;178:301-7 pubmed
    ..7-fold) and CKS1 (2.2-fold). We hypothesized that SKP2 and CKS1 gene expression is associated with urothelial carcinoma invasiveness and prognosis...
  13. Dragicevic D, Djokic M, Pekmezovic T, Micic S, Hadzi Djokic J, Vuksanovic A, et al. Survival of patients with transitional cell carcinoma of the ureter and renal pelvis in Balkan endemic nephropathy and non-endemic areas of Serbia. BJU Int. 2007;99:1357-62 pubmed
    ..To evaluate the characteristics and survival of patients with upper urinary tract (UUT) transitional cell carcinoma (TCC) in Serbia, followed for >/=5 years or until death...
  14. Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, van Oosterom A, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50-4 pubmed
    ..9%). With longer follow-up initial results have been confirmed, and shows that HD-M-VAC produces a borderline statistically significant relative reduction in the risk of progression and death compared to M-VAC...
  15. Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, et al. Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol. 2005;174:2120-3; discussion 2124 pubmed
    ..We also developed a prognostic factors-based model for risk stratification of upper tract TCC...
  16. Razdan S, Johannes J, Cox M, Bagley D. Current practice patterns in urologic management of upper-tract transitional-cell carcinoma. J Endourol. 2005;19:366-71 pubmed
    ..To determine the current practice patterns in the management of upper-tract transitional-cell carcinoma (TCC) among a large group of urologists...
  17. Palou J, Piovesan L, Huguet J, Salvador J, Vicente J, Villavicencio H. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol. 2004;172:66-9 pubmed
    ..We present long-term results of the percutaneous approach and resection of upper urinary tract transitional cell carcinoma, and we evaluate the prognostic factors related to recurrence...
  18. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-61 pubmed publisher
    ..We conducted a randomized phase III study of VFL and best supportive care (BSC) versus BSC alone in the treatment of patients with advanced TCCU who had experienced progression after a first-line platinum-containing regimen...
  19. Lee S, Hong S, Han B, Yu J, Han J, Jeong S, et al. Prognostic significance of tumor necrosis in primary transitional cell carcinoma of upper urinary tract. Jpn J Clin Oncol. 2007;37:49-55 pubmed
    ..We investigated the prognostic significance of tumor necrosis in primary transitional cell carcinoma (TCC) of upper urinary tract...
  20. Higgins J, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu S, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-80 pubmed
    ..We conclude that the detection of S100P and GATA3 protein expression may help distinguish urothelial carcinomas from other genitourinary neoplasms that enter into the differential diagnosis...
  21. Takahashi T, Higashi S, Nishiyama H, Segawa T, Nakamura E, Kinoshita H, et al. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol. 2006;36:104-8 pubmed
  22. Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, et al. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. Cancer Chemother Pharmacol. 2006;58:402-7 pubmed
  23. Johnson G, Fraiman M, Grasso M. Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int. 2005;95 Suppl 2:110-3 pubmed
  24. Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007;100:269-73 pubmed
  25. Margulis V, Shariat S, Matin S, Kamat A, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224-33 pubmed publisher
    ..A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated with poor prognosis were identified...
  26. Lin W, Hu F, Chung S, Chueh S, Pu Y, Huang K. The role of lymphovascular invasion in predicting the prognosis of clinically localized upper tract urothelial carcinoma (pT1-3cN0M0). J Urol. 2008;180:879-84; discussion 884-5 pubmed publisher
    ..We assessed the impact of lymphovascular invasion on the prognosis of patients treated for clinically localized (pT1-3N0M0) upper tract urothelial carcinoma...
  27. Li X, Xing N, Wang Y, Hu X, Yin H, Zhang X. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol. 2008;15:53-7 pubmed publisher
    ..To present a single center experience in managing transitional cell carcinoma (TCC) in Chinese renal transplant (RTx) recipients...
  28. Matsumoto K, Irie A, Satoh T, Okazaki M, Iwamura M, Baba S. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol. 2007;14:1000-4; discussion 1004 pubmed
    ..The objective of this study was to assess the tumor responses, toxicity, and overall survival of these patients as second-line treatment...
  29. Pfohl Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Mol Nutr Food Res. 2007;51:1131-46 pubmed
    ..OTA and CIT are more frequently found in rural area. AA was never detected. All these plead for implication of mycotoxins, especially OTA, in BEN and UTT...
  30. Jessen C, Agerbaek M, von der Maase H. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol. 2009;48:411-7 pubmed publisher
  31. Bader M, Sroka R, Gratzke C, Seitz M, Weidlich P, Staehler M, et al. Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol. 2009;56:65-71 pubmed publisher
    ..Ureteroscopically guided laser techniques are commonly used in the treatment of upper urinary tract transitional cell carcinoma (UUTT); however, there is an ongoing debate with regard to indication and management...
  32. Highley M, Griffiths G, Uscinska B, Huddart R, Barber J, Parmar M, et al. A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract. Clin Oncol (R Coll Radiol). 2009;21:394-400 pubmed publisher
    ..To assess the activity of a continuous infusion of 5-fluorouracil in patients with recurrent locally advanced or metastatic transitional cell carcinoma of the urinary tract...
  33. Wu M, Lian J, Yang C, Cheng C, Chen C, Lee W, et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis. 2004;43:1091-7 pubmed
    ..Herein, the authors report a very high cumulative incidence of transitional cell carcinoma (TCC) of the urinary tract after kidney transplantation in Taiwan...
  34. Grollman A, Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia. J Am Soc Nephrol. 2007;18:2817-23 pubmed
    ..Public health authorities in countries harboring this disease are encouraged to reduce the potential for dietary exposure to Aristolochia clematitis...
  35. Grollman A, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007;104:12129-34 pubmed
  36. Lai M, Wang S, Chen P, Chen Y, Wang J. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102:179-86 pubmed publisher
    ..Consumption of Chinese herbs that contain aristolochic acid (eg, Mu Tong) has been associated with an increased risk of urinary tract cancer...
  37. Fritsche H, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol. 2012;30:666-72 pubmed publisher
    ..We tested whether macroscopic tumor architecture improves outcome prediction in an international cohort of patients...
  38. Schmitz Dräger B, Lümmen G, Bismarck E, Fischer C. [Prevention of uro-oncological diseases]. Urologe A. 2012;51:727-36 pubmed publisher
    ..However, translation of these findings into urological practice remains a matter of controversial discussion. ..
  39. Schenck M, Michels Oswald W, Tschirdewahn S, Rubben H, Vom Dorp F, Rose A, et al. [How should urologists perform implantation of subcutaneous central venous port systems? A single center experience of 347 cases]. Urologe A. 2012;51:226-37 pubmed publisher
  40. Obata J, Kikuchi E, Tanaka N, Matsumoto K, Hayakawa N, Ide H, et al. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Urol Oncol. 2013;31:1725-30 pubmed publisher
    ..Patients with pre-CRP >0.5 mg/dl were strongly predicted to have worse prognostic outcomes following RNU. Due to its low cost and easy accessibility, CRP may be a useful biomarker for localized UTUC. ..
  41. Gruenberg J, Manivel J, Gupta P, Dykoski R, Mesa H. Fatal acute cardiac vasculopathy during cisplatin-gemcitabine-bevacizumab (CGB) chemotherapy for advanced urothelial carcinoma. J Infect Chemother. 2016;22:112-6 pubmed publisher
    ..We present the first case of acute, fatal cardiac failure due to microvasculopathy most consistent with bevacizumab-associated toxicity. The findings are discussed in light of the existing literature. ..
  42. Galanakis I, Spyropoulos E, Gkialas I, Nomikos A, Souka E, Mitropoulos D. ErbB2, ErbB3 and ErbB4 expression in urothelial tumors of the upper urinary tract and their prognostic significance. J BUON. 2013;18:653-9 pubmed
    ..ErbB2, however, was inversely associated with recurrence and needs further evaluation in well-designed, prospective, randomized trials. ..
  43. Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, et al. Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch. 2013;462:101-7 pubmed publisher
    ..These data suggest that nuclear accumulation of survivin represents biologic aggressiveness and that nuclear survivin is a negative prognostic marker in patients with resected UUTUC. ..
  44. Yuen J, Gohel M, Ng C. The differential immunological activities of Ganoderma lucidum on human pre-cancerous uroepithelial cells. J Ethnopharmacol. 2011;135:711-8 pubmed publisher
    ..In particular, the activities of GLe may favor the clearance of high risk urothelial cells, suggesting potent chemopreventive ingredients are extractable by ethanol from G. lucidum. ..
  45. Loughlin K. The practice of urologic oncology: some economic realties. Urol Oncol. 2012;30:S5-9 pubmed publisher
    ..Compounding these challenges is the aging of the urological workforce and projected significant manpower shortages. These multiple factors must be confronted directly or the future quality of urologic cancer care will be jeopardized. ..
  46. Rink M, Adam M, Hansen J, Chun F, Ahyai S, Remzi M, et al. [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors]. Urologe A. 2012;51:1228-39 pubmed publisher
  47. Rao S, Correa J, Sexton W, Pow Sang J, Dickinson S, Lin H, et al. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012;110:E475-80 pubmed publisher
    ..The present results indicate that modified RPLND during RNU for UUT-UC is a feasible procedure with acceptable morbidity. A larger prospective clinical trial is needed to adequately assess its potential therapeutic benefit. ..
  48. Huang H, Jiang S, Han J, Cheng Q, Dong C, Pan C. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus. J Cancer Res Clin Oncol. 2014;140:1067-73 pubmed publisher
    ..No obvious publication bias was detected. Findings from this meta-analysis indicate that SLE is associated with a decreased risk of prostate cancer and an increased risk of kidney cancer. ..
  49. Hattori S, Kikuchi E, Kosaka T, Miyazaki Y, Tanaka N, Miyajima A, et al. Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma. Ann Surg Oncol. 2016;23:663-70 pubmed publisher
    ..The protein expression of Axl and its ligand Gas6 may be a useful indicator for a worse clinical outcome in UTUC patients, especially patients with pT ≥ 2, who underwent radical nephroureterectomy. ..
  50. Nensa F, Forsting M, Wetter A. [The future of radiology: What can we expect within the next 10 years?]. Urologe A. 2016;55:350-5 pubmed publisher
  51. Haines L, Bamias A, Krege S, Lin C, Hahn N, Ecke T, et al. The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer. 2013;11:346-52 pubmed publisher
    ..Although gender-associated survival disparities in patients with metastatic urothelial cancer cannot be completely ruled out, if such disparities exist, they are unlikely related to tolerability or efficacy of chemotherapy. ..
  52. Nita G, Georgescu D, Multescu R, Dragutescu M, Mihai B, Geavlete B, et al. Prognostic factors in laser treatment of upper urinary tract urothelial tumours. J Med Life. 2012;5:33-8 pubmed
    ..The most important prognostic factors for UUT-UCCs evolution are tumours location, size and mostly tumour grade. The patients' compliance is very important for detecting recurrences. ..
  53. Pond G, Agarwal N, Bellmunt J, Choueiri T, Qu A, Fougeray R, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014;113:E137-43 pubmed publisher
  54. García Donas J, Font A, Pérez Valderrama B, Virizuela J, Climent M, Hernando Polo S, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled,. Lancet Oncol. 2017;18:672-681 pubmed publisher
    ..Vinflunine maintenance had an acceptable safety profile. Further studies of the role of vinflunine are warranted. Pierre-Fabre Médicament. ..
  55. Pond G, Bellmunt J, Fougeray R, Choueiri T, Qu A, Niegisch G, et al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013;11:495-500 pubmed publisher
  56. Xiao J, Zhu X, Hao G, Zhu Y, Hou H, Zhang J, et al. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations. Transplant Proc. 2011;43:3751-4 pubmed publisher
    ..We sought to investigate the association between urothelial carcinoma (UC) after kidney transplantation and aristolochic acid (AA) exposure, and to explore the potential role of AA in HRas and TP53 gene mutations...
  57. Fischer N, Göke F, Splittstösser V, Lankat Buttgereit B, Muller S, Ellinger J. Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. Biochem Biophys Res Commun. 2012;417:29-34 pubmed publisher
    ..We investigated the role of the programmed cell death 4 (PDCD4) tumor suppressor gene in specimens of transitional cell carcinoma and of healthy individuals...
  58. Todenhöfer T, Hennenlotter J, Tews V, Gakis G, Aufderklamm S, Kuehs U, et al. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol. 2013;31:1148-54 pubmed publisher
  59. Andres G, Ashour N, Sanchez Chapado M, Ropero S, Angulo J. The study of DNA methylation in urological cancer: present and future. Actas Urol Esp. 2013;37:368-75 pubmed publisher
    ..We have synthesized the principal advances in the field of the study of epigenetics and specifically DNA methylation regarding the diagnosis of urological neoplasms...
  60. Win A, Lindor N, Winship I, Tucker K, Buchanan D, Young J, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013;105:274-9 pubmed publisher
    ..We estimated cancer risks following an endometrial cancer diagnosis for women carrying MMR gene mutations...
  61. Makanjuola J, Aggoun A, Swash M, Grange P, Challacombe B, Dasgupta P. 3D-holoscopic imaging: a new dimension to enhance imaging in minimally invasive therapy in urologic oncology. J Endourol. 2013;27:535-9 pubmed publisher
    ..This technology is based on physical principles with duplication of light fields. The 3D content is captured in real time with the content viewed by multiple viewers independently of their position, without 3D eyewear...
  62. Gallagher D, Vijai J, Hamilton R, Ostrovnaya I, Iyer G, Garcia Grossman I, et al. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Ann Oncol. 2013;24:2414-21 pubmed publisher
    ..We hypothesized that variations in germline DNA may contribute to UC chemosensitivity...
  63. Fujita K, Tanigawa G, Imamura R, Nakagawa M, Hayashi T, Kishimoto N, et al. Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. Int J Urol. 2013;20:594-601 pubmed publisher
    ..To assess the impact of preoperative serum sodium concentration on the prognosis of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy...
  64. Yamamoto Y, Misumi T, Eguchi S, Chochi Y, Kitahara S, Nakao M, et al. Centrosome amplification as a putative prognostic biomarker for the classification of urothelial carcinomas. Hum Pathol. 2011;42:1923-30 pubmed publisher
    ..0405 and P = .0020, respectively). Thus, these data suggest that centrosome amplification may have great potential as a biomarker for improved objective classification of urothelial carcinoma and estimation of prognosis...
  65. Burger M, Shariat S, Fritsche H, Martinez Salamanca J, Matsumoto K, Chromecki T, et al. No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. World J Urol. 2011;29:465-72 pubmed publisher
    ..The purpose of the present study was to evaluate the impact of LND on clinical outcomes in a large multicenter series of RNU for UTUC...
  66. Wittekind C, Karl A. [Uropathology - requirements for standards and quality]. Urologe A. 2013;52:958-64 pubmed publisher
    ..There are German pathology guidelines for tumors of the prostate, testis, kidneys, renal pelvis, urethra and urinary bladder...
  67. Barkan G, Wojcik E. Genitourinary cytopathology (kidney and urinary tract). Cancer Treat Res. 2014;160:149-83 pubmed publisher
    ..Most of these tests have not added much to the diagnostic evaluation. Combining some of the new markers with each other and/or cytologic evaluation may optimize their performance status...
  68. Hou C, Chang P, Chen C, Lin Y, Tsui K. Does adequate bladder cuff excision impact outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. Chang Gung Med J. 2011;34:496-505 pubmed
    ..Nephroureterectomy with bladder cuff excision has been the gold standard surgical treatment for upper tract urothelial carcinoma. In this study, we determined the independent prognostic factors for upper tract urothelial carcinoma...